ROS1 Fusions in Cancer: A Review

References

• Bongarzone I , MonziniN, BorrelloMGet al. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A. Mol. Cell Biol.13, 358–366 (1993).
   PubMed Web of Science ®Google Scholar
• Tognon C , KnezevichSR, HuntsmanDet al. Expression of the ETV6–NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell2, 367–376 (2002).
   PubMed Web of Science ®Google Scholar
• Rikova K , GuoA, ZengQet al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell131, 1190–1203 (2007).
   PubMed Web of Science ®Google Scholar
• Shaw AT , HsuPP, AwadMM, EngelmanJA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat. Rev. Cancer13, 772–787 (2013).
   PubMed Web of Science ®Google Scholar
• El-Deeb IM , YooKH, LeeSH. ROS receptor tyrosine kinase: a new potential target for anticancer drugs. Med. Res. Rev.31, 794–818 (2011).
   PubMed Web of Science ®Google Scholar
• Gainor JF , ShawAT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist18, 865–875 (2013).
   PubMed Web of Science ®Google Scholar
• Khoo C , RogersTM, FellowesA, BellA, FoxS. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Transl. Lung Cancer Res.4, 126–141 (2015).
   PubMed Web of Science ®Google Scholar
• Acquaviva J , WongR, CharestA. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim. Biophys. Acta1795, 37–52 (2009).
   PubMed Web of Science ®Google Scholar
• Shibuya M , HanafusaH, BalduzziPC. Cellular sequences related to three new onc genes of avian sarcoma virus (FPS, yes, and ros) and their expression in normal and transformed cells. J. Virol.42, 143–152 (1982).
   PubMed Web of Science ®Google Scholar
• Matsushime H , WangLH, ShibuyaM. Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule. Mol. Cell Biol.6, 3000–3004 (1986).
   PubMed Web of Science ®Google Scholar
• Nagarajan L , LouieE, TsujimotoY, BalduzziPC, HuebnerK, CroceCM. The human c-ros gene (ROS) is located at chromosome region 6q16–6q22. Proc. Natl Acad. Sci. USA83, 6568–6572 (1986).
   PubMed Web of Science ®Google Scholar
• Satoh H , YoshidaMC, MatsushimeH, ShibuyaM, SasakiM. Regional localization of the human c-ros-1 on 6q22 and flt on 13q12. Jpn. J. Cancer Res.78, 772–775 (1987).
   PubMedGoogle Scholar
• Zong CS , ZengL, JiangY, SadowskiHB, WangLH. Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. J. Biol. Chem.273, 28065–28072 (1998).
   PubMed Web of Science ®Google Scholar
• Birchmeier C , O’NeillK, RiggsM, WiglerM. Characterization of ROS1 cDNA from a human glioblastoma cell line. Proc. Natl Acad. Sci. USA87, 4799–4803 (1990).
   PubMed Web of Science ®Google Scholar
• Zeng L , SachdevP, YanLet al. Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol. Cell Biol.20, 9212–9224 (2000).
   PubMed Web of Science ®Google Scholar
• Nguyen KT , ZongCS, UttamsinghSet al. The role of phosphatidylinositol 3-kinase, rho family GTPases, and STAT3 in Ros-induced cell transformation. J. Biol. Chem.277, 11107–11115 (2002).
   PubMed Web of Science ®Google Scholar
• Zong CS , ChanJL, YangSK, WangLH. Mutations of Ros differentially effecting signal transduction pathways leading to cell growth versus transformation. J. Biol. Chem.272, 1500–1506 (1997).
   PubMed Web of Science ®Google Scholar
• Keilhack H , MullerM, BohmerSAet al. Negative regulation of Ros receptor tyrosine kinase signaling. An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1. J. Cell Biol.152, 325–334 (2001).
   PubMed Web of Science ®Google Scholar
• Charest A , WilkerEW, McLaughlinMEet al. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res.66, 7473–7481 (2006).
   PubMed Web of Science ®Google Scholar
• Poole AW , JonesML. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signal.17, 1323–1332 (2005).
   PubMed Web of Science ®Google Scholar
• Robinson DR , WuYM, LinSF. The protein tyrosine kinase family of the human genome. Oncogene19, 5548–5557 (2000).
   PubMed Web of Science ®Google Scholar
• Palmer RH , VernerssonE, GrabbeC, HallbergB. Anaplastic lymphoma kinase: signalling in development and disease. Biochem. J.420, 345–361 (2009).
   PubMed Web of Science ®Google Scholar
• De Braekeleer M , De BraekeleerE, Douet-GuilbertN. Whole genome/exome sequencing in acute leukemia: from research to clinics. In: Next Generation Sequencing in Cancer Research, Volume 2 From Basepairs to Bedsides. WuW, ChoudhryH ( Eds). Springer Publisher, Cham, Switzerland, 381–400 (2015).
   Google Scholar
• Giacomini CP , SunS, VarmaSet al. Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. PLoS. Genet.9, e1003464 (2013).
   PubMed Web of Science ®Google Scholar
• Pan Y , ZhangY, LiYet al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer84, 121–126 (2014).
   PubMed Web of Science ®Google Scholar
• Wang R , HuH, PanYet al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J. Clin. Oncol30, 4352–4359 (2012).
   PubMed Web of Science ®Google Scholar
• Wang R , PanY, LiCet al. The use of quantitative real-time reverse transcriptase PCR for 5’ and 3’ portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin. Cancer Res.18, 4725–4732 (2012).
   PubMed Web of Science ®Google Scholar
• Yoshida A , KohnoT, TsutaKet al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am. J. Surg. Pathol.37, 554–562 (2013).
   PubMed Web of Science ®Google Scholar
• Cai W , LiX, SuCet al. ROS1 fusions in Chinese patients with non-small-cell lung cancer. Ann. Oncol.24, 1822–1827 (2013).
   PubMed Web of Science ®Google Scholar
• Chen YF , HsiehMS, WuSGet al. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in east Asian populations. J. Thorac. Oncol.9, 1171–1179 (2014).
   PubMed Web of Science ®Google Scholar
• Rimkunas VM , CrosbyKE, LiDet al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG–ROS1 fusion. Clin. Cancer Res.18, 4449–4457 (2012).
   PubMed Web of Science ®Google Scholar
• Sholl LM , SunH, ButaneyMet al. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am. J. Surg. Pathol.37, 1441–1449 (2013).
   PubMed Web of Science ®Google Scholar
• Yoshida A , TsutaK, WakaiSet al. Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod. Pathol.27, 711–720 (2014).
   PubMed Web of Science ®Google Scholar
• Boyle TA , MasagoK, EllisonKE, YatabeY, HirschFR. ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin. Lung Cancer16, 106–111 (2015).
   PubMed Web of Science ®Google Scholar
• Rogers TM , RussellPA, WrightGet al. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. J. Thorac. Oncol.10, 611–618 (2015).
   PubMed Web of Science ®Google Scholar
• Hornick JL , ShollLM, DalCP, ChildressMA, LovlyCM. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. Mod. Pathol.28, 732–739 (2015).
   PubMed Web of Science ®Google Scholar
• Shan L , LianF, GuoLet al. Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR. PLoS ONE10, e0120422 (2015).
   PubMed Web of Science ®Google Scholar
• Uguen A , MarcorellesP, De BraekeleerM. Searching for ROS1 rearrangements in lung cancer by fluorescent in situ hybridization: the importance of probe design. J. Thorac. Oncol.10, e83–e85 (2015).
   PubMed Web of Science ®Google Scholar
• Takeuchi K , SodaM, TogashiYet al. RET, ROS1 and ALK fusions in lung cancer. Nat. Med.18, 378–381 (2012).
   PubMed Web of Science ®Google Scholar
• Antonescu CR , SuurmeijerAJ, ZhangLet al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am. J. Surg. Pathol.39, 957–967 (2015).
   PubMed Web of Science ®Google Scholar
• Davies KD , LeAT, TheodoroMFet al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin. Cancer Res.18, 4570–4579 (2012).
   PubMed Web of Science ®Google Scholar
• Bergethon K , ShawAT, OuSHet al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol.30, 863–870 (2012).
   PubMed Web of Science ®Google Scholar
• Wiesner T , HeJ, YelenskyRet al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat. Commun.5, 3116 (2014).
   PubMed Web of Science ®Google Scholar
• Go H , KimDW, KimDet al. Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. J. Thorac. Oncol8, 1445–1450 (2013).
   PubMed Web of Science ®Google Scholar
• Mescam-Mancini L , LantuejoulS, Moro-SibilotDet al. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer83, 168–173 (2014).
   PubMed Web of Science ®Google Scholar
• Kim MH , ShimHS, KangDRet al. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Lung Cancer83, 389–395 (2014).
   PubMed Web of Science ®Google Scholar
• Warth A , MuleyT, DienemannHet al. ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology65, 187–194 (2014).
   PubMed Web of Science ®Google Scholar
• Okamoto I , SakaiK, MoritaSet al. Multiplex genomic profiling of non-small cell lung cancers from the LETS Phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget5, 2293–2304 (2014).
   PubMed Web of Science ®Google Scholar
• Scheffler M , SchultheisA, TeixidoCet al. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget6, 10577–10585 (2015).
   PubMed Web of Science ®Google Scholar
• Birchmeier C , SharmaS, WiglerM. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc. Natl Acad. Sci. USA84, 9270–9274 (1987).
   PubMed Web of Science ®Google Scholar
• De Braekeleer M , De BraekeleerE, Douet-GuilbertN. Geographic/ethnic variability of chromosomal and molecular abnormalities in leukemia. Expert Rev. Anticancer Ther.15, 1093–1102 (2015).
   PubMed Web of Science ®Google Scholar
• Lee J , LeeSE, KangSYet al. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer119, 1627–1635 (2013).
   PubMed Web of Science ®Google Scholar
• Aisner DL , NguyenTT, PaskulinDDet al. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol. Cancer Res.12, 111–118 (2014).
   PubMed Web of Science ®Google Scholar
• Peraldo-Neia C , CavalloniG, BalsamoAet al. Screening for the FIG–ROS1 fusion in biliary tract carcinomas by nested PCR. Genes Chromosomes Cancer53, 1033–1040 (2014).
   PubMed Web of Science ®Google Scholar
• Graham RP , Barr FritcherEG, PestovaEet al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum. Pathol.45, 1630–1638 (2014).
   PubMed Web of Science ®Google Scholar
• Liu P , WuY, SunL, ZuoQ, ShiM. ROS kinase fusions are not common in Chinese patients with cholangiocarcinoma. J. South Med. Univ.33, 474–478 (2013).
   Google Scholar
• Gu TL , DengX, HuangFet al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS ONE6, e15640 (2011).
   PubMed Web of Science ®Google Scholar
• Lovly CM , GuptaA, LipsonDet al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov.4, 889–895 (2014).
   PubMed Web of Science ®Google Scholar
• Lee HJ , SeolHS, KimJYet al. ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms. Ann. Surg. Oncol.20, 200–208 (2013).
   PubMed Web of Science ®Google Scholar
• Charest A , LaneK, McMahonK, HousmanDE. Association of a novel PDZ domain-containing peripheral Golgi protein with the Q-SNARE (Q-soluble N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein receptor) protein syntaxin 6. J. Biol. Chem.276, 29456–29465 (2001).
   PubMed Web of Science ®Google Scholar
• Charest A , LaneK, McMahonKet al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer37, 58–71 (2003).
   PubMed Web of Science ®Google Scholar
• Suehara Y , ArcilaM, WangLet al. Identification of KIF5B–RET and GOPC–ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin. Cancer Res.18, 6599–6608 (2012).
   PubMed Web of Science ®Google Scholar
• Charest A , KheifetsV, ParkJet al. Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. Proc. Natl Acad. Sci. USA100, 916–921 (2003).
   PubMed Web of Science ®Google Scholar
• Murer H , ForsterI, BiberJ. The sodium phosphate cotransporter family SLC34. Pflugers Arch.447, 763–767 (2004).
   PubMed Web of Science ®Google Scholar
• Shaw AT , OuSH, BangYJet al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med.371, 1963–1971 (2014).
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network . Comprehensive molecular profiling of lung adenocarcinoma. Nature511, 543–550 (2014).
   PubMed Web of Science ®Google Scholar
• Lee SE , LeeB, HongMet al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Mod. Pathol.28, 468–479 (2015).
   PubMed Web of Science ®Google Scholar
• Jun HJ , JohnsonH, BronsonRT, deFS, WhiteF, CharestA. The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. Cancer Res.72, 3764–3774 (2012).
   PubMed Web of Science ®Google Scholar
• Leng L , MetzCN, FangYet al. MIF signal transduction initiated by binding to CD74. J. Exp. Med.197, 1467–1476 (2003).
   PubMed Web of Science ®Google Scholar
• Li C , FangR, SunYet al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from east Asian never smokers. PLoS ONE6, e28204 (2011).
   PubMed Web of Science ®Google Scholar
• Kim HR , LimSM, KimHJet al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann. Oncol.24, 2364–2370 (2013).
   PubMed Web of Science ®Google Scholar
• Min SW , ChangWP, SudhofTC. E-Syts, a family of membranous Ca2+-sensor proteins with multiple C2 domains. Proc. Natl Acad. Sci. USA104, 3823–3828 (2007).
   PubMed Web of Science ®Google Scholar
• Majewski IJ , MittempergherL, DavidsonNMet al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J. Pathol.230, 270–276 (2013).
   PubMed Web of Science ®Google Scholar
• Parker BC , AnnalaMJ, CogdellDEet al. The tumorigenic FGFR3–TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J. Clin. Invest.123, 855–865 (2013).
   PubMed Web of Science ®Google Scholar
• Spath-Schwalbe E , FlathB, KaufmannOet al. An unusual case of leukemic non-Hodgkin’s lymphoma with blastic transformation. Ann. Hematol.79, 217–221 (2000).
   PubMed Web of Science ®Google Scholar
• Neri A , ChangCC, LombardiLet al. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell67, 1075–1087 (1991).
   PubMed Web of Science ®Google Scholar
• Crescenzo R , AbateF, LasorsaEet al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell27, 516–532 (2015).
   PubMed Web of Science ®Google Scholar
• Ordentlich P , DownesM, XieW, GeninA, SpinnerNB, EvansRM. Unique forms of human and mouse nuclear receptor corepressor SMRT. Proc. Natl Acad. Sci. USA96, 2639–2644 (1999).
   PubMed Web of Science ®Google Scholar
• Li J , WangJ, WangJet al. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J.19, 4342–4350 (2000).
   PubMed Web of Science ®Google Scholar
• Park EJ , SchroenDJ, YangM, LiH, LiL, ChenJD. SMRTe, a silencing mediator for retinoid and thyroid hormone receptors-extended isoform that is more related to the nuclear receptor corepressor. Proc. Natl Acad. Sci. USA96, 3519–3524 (1999).
   PubMed Web of Science ®Google Scholar
• Joshi P , GrecoTM, GuiseAJet al. The functional interactome landscape of the human histone deacetylase family. Mol. Syst. Biol.9, 672 (2013).
   PubMed Web of Science ®Google Scholar
• Jiang Q , Galiegue-ZouitinaS, RoumierC, HildebrandMP, ThomasS, CoignetLJ. Genomic organization and refined mapping of the human nuclear corepressor 2 (NCOR2)/silencing mediator of retinoid and thyroid hormone receptor (SMRT) gene on chromosome 12q24.3. Cytogenet. Cell Genet.92, 217–220 (2001).
   PubMedGoogle Scholar
• Lewis MJ , PelhamHR. Sequence of a second human KDEL receptor. J. Mol. Biol.226, 913–916 (1992).
   PubMed Web of Science ®Google Scholar
• Govindan R , DingL, GriffithMet al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell150, 1121–1134 (2012).
   PubMed Web of Science ®Google Scholar
• Elfenbein A , SimonsM. Syndecan-4 signaling at a glance. J. Cell Sci.126, 3799–3804 (2013).
   PubMed Web of Science ®Google Scholar
• Huang CP , ChengCM, SuHL, LinYW. Syndecan-4 promotes epithelial tumor cells spreading and regulates the turnover of PKCalpha activity under mechanical stimulation on the elastomeric substrates. Cell Physiol. Biochem.36, 1291–1304 (2015).
   PubMedGoogle Scholar
• Woods A , CouchmanJR. Syndecan-4 and focal adhesion function. Curr. Opin. Cell Biol.13, 578–583 (2001).
   PubMed Web of Science ®Google Scholar
• Echtermeyer F , BertrandJ, DreierRet al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat. Med.15, 1072–1076 (2009).
   PubMed Web of Science ®Google Scholar
• Choi Y , KangD, HanIO, OhES. Hierarchy between the transmembrane and cytoplasmic domains in the regulation of syndecan-4 functions. Cell Signal.24, 1522–1530 (2012).
   PubMed Web of Science ®Google Scholar
• Grieco M , CerratoA, SantoroM, FuscoA, MelilloRM, VecchioG. Cloning and characterization of H4 (D10S170), a gene involved in RET rearrangements in vivo. Oncogene9, 2531–2535 (1994).
   PubMed Web of Science ®Google Scholar
• Merolla F , PentimalliF, PacelliRet al. Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage. Oncogene26, 6167–6175 (2007).
   PubMed Web of Science ®Google Scholar
• Leone V , MansuetoG, PierantoniGMet al. CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1. Oncogene29, 4341–4351 (2010).
   PubMed Web of Science ®Google Scholar
• Kulkarni S , HeathC, ParkerSet al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR–ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res.60, 3592–3598 (2000).
   PubMed Web of Science ®Google Scholar
• Celetti A , CerratoA, MerollaF, VitaglianoD, VecchioG, GriecoM. H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization. Oncogene23, 109–121 (2004).
   PubMed Web of Science ®Google Scholar
• Matsubara D , KanaiY, IshikawaSet al. Identification of CCDC6–RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J. Thorac. Oncol.7, 1872–1876 (2012).
   PubMed Web of Science ®Google Scholar
• Seo JS , JuYS, LeeWCet al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res.22, 2109–2119 (2012).
   PubMed Web of Science ®Google Scholar
• Thanasopoulou A , StravopodisDJ, DimasKS, SchwallerJ, AnastasiadouE. Loss of CCDC6 affects cell cycle through impaired intra-S-phase checkpoint control. PLoS ONE7, e31007 (2012).
   PubMed Web of Science ®Google Scholar
• Staibano S , IlardiG, LeoneVet al. Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors. BMC Cancer13, 433 (2013).
   PubMed Web of Science ®Google Scholar
• Gould KL , BretscherA, EschFS, HunterT. cDNA cloning and sequencing of the protein-tyrosine kinase substrate, ezrin, reveals homology to band 4.1. EMBO J.8, 4133–4142 (1989).
   PubMed Web of Science ®Google Scholar
• Tsukita S , YonemuraS. Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins. J. Biol. Chem.274, 34507–34510 (1999).
   PubMed Web of Science ®Google Scholar
• Fehon RG , McClatcheyAI, BretscherA. Organizing the cell cortex: the role of ERM proteins. Nat. Rev. Mol. Cell Biol.11, 276–287 (2010).
   PubMed Web of Science ®Google Scholar
• Wang X , LiuM, ZhaoCY. Expression of ezrin and moesin related to invasion, metastasis and prognosis of laryngeal squamous cell carcinoma. Genet. Mol. Res.13, 8002–8013 (2014).
   PubMed Web of Science ®Google Scholar
• Arai Y , TotokiY, TakahashiHet al. Mouse model for ROS1-rearranged lung cancer. PLoS ONE8, e56010 (2013).
   PubMedGoogle Scholar
• Tort F , PinyolM, PulfordKet al. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab. Invest.81, 419–426 (2001).
   PubMed Web of Science ®Google Scholar
• Karube K , CampoE. MYC alterations in diffuse large B-cell lymphomas. Semin. Hematol.52, 97–106 (2015).
   PubMed Web of Science ®Google Scholar
• Chmielecki J , PeiferM, VialeAet al. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204–PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. Genes Chromosomes Cancer51, 54–65 (2012).
   PubMed Web of Science ®Google Scholar
• Lang CM , FellererK, SchwenkBMet al. Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J. Biol. Chem.287, 19355–19365 (2012).
   PubMed Web of Science ®Google Scholar
• Brady OA , ZhengY, MurphyK, HuangM, HuF. The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum. Mol. Genet.22, 685–695 (2013).
   PubMed Web of Science ®Google Scholar
• Stagi M , KleinZA, GouldTJ, BewersdorfJ, StrittmatterSM. Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B. Mol. Cell Neurosci.61, 226–240 (2014).
   PubMed Web of Science ®Google Scholar
• Ou SH , ChalmersZR, AzadaMCet al. Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling. Lung Cancer88, 352–354 (2015).
   PubMed Web of Science ®Google Scholar
• Dodge GR , KovalszkyI, McBrideOWet al. Human clathrin heavy chain (CLTC): partial molecular cloning, expression, and mapping of the gene to human chromosome 17q11-qter. Genomics11, 174–178 (1991).
   PubMed Web of Science ®Google Scholar
• Royle SJ , BrightNA, LagnadoL. Clathrin is required for the function of the mitotic spindle. Nature434, 1152–1157 (2005).
   PubMed Web of Science ®Google Scholar
• Bridge JA , KanamoriM, MaZet al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am. J. Pathol.159, 411–415 (2001).
   PubMed Web of Science ®Google Scholar
• Patel AS , MurphyKM, HawkinsALet al. RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors. Cancer Genet. Cytogenet.176, 107–114 (2007).
   PubMedGoogle Scholar
• De Paepe P , BaensM, van KriekenHet al. ALK activation by the CLTC–ALK fusion is a recurrent event in large B-cell lymphoma. Blood102, 2638–2641 (2003).
   PubMed Web of Science ®Google Scholar
• McManus DT , CatherwoodMA, CareyPD, CuthbertRJ, AlexanderHD. ALK-positive diffuse large B-cell lymphoma of the stomach associated with a clathrin-ALK rearrangement. Hum. Pathol.35, 1285–1288 (2004).
   PubMed Web of Science ®Google Scholar
• Wang WY , GuL, LiuWP, LiGD, LiuHJ, MaZG. ALK-positive extramedullary plasmacytoma with expression of the CLTC–ALK fusion transcript. Pathol. Res. Pract.207, 587–591 (2011).
   PubMed Web of Science ®Google Scholar
• Tokuda K , Eguchi-IshimaeM, YagiCet al. CLTC–ALK fusion as a primary event in congenital blastic plasmacytoid dendritic cell neoplasm. Genes Chromosomes Cancer53, 78–89 (2014).
   PubMed Web of Science ®Google Scholar
• Argani P , LuiMY, CouturierJ, BouvierR, FournetJC, LadanyiM. A novel CLTC–TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene22, 5374–5378 (2003).
   PubMed Web of Science ®Google Scholar
• Carnahan J , BeltranPJ, BabijCet al. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol. Cancer Ther.9, 2399–2410 (2010).
   PubMed Web of Science ®Google Scholar
• Maul RS , ChangDG. EPLIN, epithelial protein lost in neoplasm. Oncogene18, 7838–7841 (1999).
   PubMed Web of Science ®Google Scholar
• Han MY , KosakoH, WatanabeT, HattoriS. Extracellular signal-regulated kinase/mitogen-activated protein kinase regulates actin organization and cell motility by phosphorylating the actin cross-linking protein EPLIN. Mol. Cell Biol.27, 8190–8204 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang S , WangX, IqbalSet al. Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition. J. Biol. Chem.288, 1469–1479 (2013).
   PubMed Web of Science ®Google Scholar
• Espindola FS , EspreaficoEM, CoelhoMVet al. Biochemical and immunological characterization of p190-calmodulin complex from vertebrate brain: a novel calmodulin-binding myosin. J. Cell Biol.118, 359–368 (1992).
   PubMed Web of Science ®Google Scholar
• Pastural E , BarratFJ, Dufourcq-LagelouseRet al. Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. Nat. Genet.16, 289–292 (1997).
   PubMed Web of Science ®Google Scholar
• Izidoro-Toledo TC , BorgesAC, AraujoDDet al. A myosin-Va tail fragment sequesters dynein light chains leading to apoptosis in melanoma cells. Cell Death. Dis.4, e547 (2013).
   PubMed Web of Science ®Google Scholar
• Roberts KG , LiY, Payne-TurnerDet al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med.371, 1005–1015 (2014).
   PubMed Web of Science ®Google Scholar
• Kriajevska M , Fischer-LarsenM, MoertzEet al. Liprin beta 1, a member of the family of LAR transmembrane tyrosine phosphatase-interacting proteins, is a new target for the metastasis-associated protein S100A4 (Mts1). J. Biol. Chem.277, 5229–5235 (2002).
   PubMed Web of Science ®Google Scholar
• Takeuchi K , SodaM, TogashiYet al. Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. Clin. Cancer Res.17, 3341–3348 (2011).
   PubMed Web of Science ®Google Scholar
• Yokota T , NakataT, MinamiS, InazawaJ, EmiM. Genomic organization and chromosomal mapping of ELKS, a gene rearranged in a papillary thyroid carcinoma. J. Hum. Genet.45, 6–11 (2000).
   PubMed Web of Science ®Google Scholar
• Ko J , NaM, KimS, LeeJR, KimE. Interaction of the ERC family of RIM-binding proteins with the liprin-alpha family of multidomain proteins. J. Biol. Chem.278, 42377–42385 (2003).
   PubMedGoogle Scholar
• Astro V , ChiarettiS, MagistratiE, FivazM, deC I. Liprin-alpha1, ERC1 and LL5 define polarized and dynamic structures that are implicated in cell migration. J. Cell Sci.127, 3862–3876 (2014).
   PubMed Web of Science ®Google Scholar
• Nakata T , KitamuraY, ShimizuKet al. Fusion of a novel gene, ELKS, to RET due to translocation t(10;12)(q11;p13) in a papillary thyroid carcinoma. Genes Chromosomes Cancer25, 97–103 (1999).
   PubMed Web of Science ®Google Scholar
• Gorello P , LaSR, BrandimarteLet al. A PDGFRB-positive acute myeloid malignancy with a new t(5;12)(q33;p13.3) involving the ERC1 gene. Leukemia22, 216–218 (2008).
   PubMed Web of Science ®Google Scholar
• Stec I , NaglSB, Van OmmenGJ, den DunnenJT. The PWWP domain: a potential protein-protein interaction domain in nuclear proteins influencing differentiation?FEBS Lett.473, 1–5 (2000).
   PubMed Web of Science ®Google Scholar
• Vermeulen M , EberlHC, MatareseFet al. Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers. Cell142, 967–980 (2010).
   PubMed Web of Science ®Google Scholar
• Qin S , MinJ. Structure and function of the nucleosome-binding PWWP domain. Trends Biochem. Sci.39, 536–547 (2014).
   PubMed Web of Science ®Google Scholar
• Pierre P , ScheelJ, RickardJE, KreisTE. CLIP-170 links endocytic vesicles to microtubules. Cell70, 887–900 (1992).
   PubMed Web of Science ®Google Scholar
• Slep KC . Structural and mechanistic insights into microtubule end-binding proteins. Curr. Opin. Cell Biol.22, 88–95 (2010).
   PubMed Web of Science ®Google Scholar
• Galjart N . CLIPs and CLASPs and cellular dynamics. Nat. Rev. Mol. Cell Biol.6, 487–498 (2005).
   PubMed Web of Science ®Google Scholar
• Gustafson MP , WelckerM, HwangHC, ClurmanBE. Zcchc8 is a glycogen synthase kinase-3 substrate that interacts with RNA-binding proteins. Biochem. Biophys. Res. Commun.338, 1359–1367 (2005).
   PubMed Web of Science ®Google Scholar
• Toriyama M , ShimadaT, KimKBet al. Shootin1: A protein involved in the organization of an asymmetric signal for neuronal polarization. J. Cell Biol.175, 147–157 (2006).
   PubMed Web of Science ®Google Scholar
• Shimada T , ToriyamaM, UemuraKet al. Shootin1 interacts with actin retrograde flow and L1-CAM to promote axon outgrowth. J. Cell Biol.181, 817–829 (2008).
   PubMed Web of Science ®Google Scholar
• Sapir T , LevyT, SakakibaraA, RabinkovA, MiyataT, ReinerO. Shootin1 acts in concert with KIF20B to promote polarization of migrating neurons. J. Neurosci.33, 11932–11948 (2013).
   PubMed Web of Science ®Google Scholar
• MacLeod AR , HoulkerC, ReinachFC, TalbotK. The mRNA and RNA-copy pseudogenes encoding TM30nm, a human cytoskeletal tropomyosin. Nucleic Acids Res.14, 8413–8426 (1986).
   PubMed Web of Science ®Google Scholar
• Lehman W , HatchV, KormanVet al. Tropomyosin and actin isoforms modulate the localization of tropomyosin strands on actin filaments. J. Mol. Biol.302, 593–606 (2000).
   PubMed Web of Science ®Google Scholar
• Butti MG , BongarzoneI, FerraresiG, MondelliniP, BorrelloMG, PierottiMA. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics28, 15–24 (1995).
   PubMed Web of Science ®Google Scholar
• Martin-Zanca D , HughesSH, BarbacidM. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature319, 743–748 (1986).
   PubMed Web of Science ®Google Scholar
• Ardini E , BosottiR, BorgiaALet al. The TPM3–NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol. Oncol.8, 1495–1507 (2014).
   PubMed Web of Science ®Google Scholar
• Lawrence B , Perez-AtaydeA, HibbardMKet al. TPM3–ALK and TPM4–ALK oncogenes in inflammatory myofibroblastic tumors. Am. J. Pathol.157, 377–384 (2000).
   PubMed Web of Science ®Google Scholar
• Lamant L , DastugueN, PulfordK, DelsolG, MariameB. A new fusion gene TPM3–ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood93, 3088–3095 (1999).
   PubMed Web of Science ®Google Scholar
• Li Z , YangR, ZhaoJet al. Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3–PDGFRB fusion. Pediatr. Blood Cancer56, 463–466 (2011).
   PubMed Web of Science ®Google Scholar
• Rosati R , LaSR, LucianoLet al. TPM3/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukemia. Leukemia20, 1623–1624 (2006).
   PubMed Web of Science ®Google Scholar
• Amano Y , IshikawaR, SakataniTet al. Oncogenic TPM3–ALK activation requires dimerization through the coiled-coil structure of TPM3. Biochem. Biophys. Res. Commun.457, 457–460 (2015).
   PubMed Web of Science ®Google Scholar
• Guo D , HolmlundC, HenrikssonR, HedmanH. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics84, 157–165 (2004).
   PubMed Web of Science ®Google Scholar
• Cai M , HanL, ChenRet al. Inhibition of LRIG3 gene expression via RNA interference modulates the proliferation, cell cycle, cell apoptosis, adhesion and invasion of glioblastoma cell (GL15). Cancer Lett.278, 104–112 (2009).
   PubMed Web of Science ®Google Scholar
• Sumimoto H , KamakuraS, ItoT. Structure and function of the PB1 domain, a protein interaction module conserved in animals, fungi, amoebas, and plants. Sci. STKE2007, re6 (2007).
   PubMedGoogle Scholar
• Miranda C , RoccatoE, RahoG, PagliardiniS, PierottiMA, GrecoA. The TFG protein, involved in oncogenic rearrangements, interacts with TANK and NEMO, two proteins involved in the NF-kappaB pathway. J. Cell Physiol208, 154–160 (2006).
   PubMed Web of Science ®Google Scholar
• Dutton-Regester K , AoudeLG, NancarrowDJet al. Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene. Genes Chromosomes Cancer51, 452–461 (2012).
   PubMed Web of Science ®Google Scholar
• Greco A , MarianiC, MirandaCet al. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol. Cell Biol.15, 6118–6127 (1995).
   PubMed Web of Science ®Google Scholar
• Mencinger M , PanagopoulosI, AndreassonP, LassenC, MitelmanF, AmanP. Characterization and chromosomal mapping of the human TFG gene involved in thyroid carcinoma. Genomics41, 327–331 (1997).
   PubMed Web of Science ®Google Scholar
• Hernandez L , PinyolM, HernandezSet al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG–ALK translocations. Blood94, 3265–3268 (1999).
   PubMed Web of Science ®Google Scholar
• Hisaoka M , IshidaT, ImamuraT, HashimotoH. TFG is a novel fusion partner of NOR1 in extraskeletal myxoid chondrosarcoma. Genes Chromosomes. Cancer40, 325–328 (2004).
   PubMed Web of Science ®Google Scholar
• Fujita H , YoshidaA, TaniguchiH, KataiH, SekineS. Adult-onset inflammatory myofibroblastic tumour of the stomach with a TFG–ROS1 fusion. Histopathology66, 610–612 (2015).
   PubMed Web of Science ®Google Scholar
• Greco A , FusettiL, MirandaCet al. Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK–T3 oncogene. Oncogene16, 809–816 (1998).
   PubMed Web of Science ®Google Scholar
• Roccato E , PagliardiniS, ClerisLet al. Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation. Oncogene22, 807–818 (2003).
   PubMed Web of Science ®Google Scholar
• Che XH , ChenH, XuZM, ShangC, SunKL, FuWN. 14-13-3epsilon contributes to tumour suppression in laryngeal carcinoma by affecting apoptosis and invasion. BMC Cancer10, 306 (2010).
   PubMed Web of Science ®Google Scholar
• Han D , YeG, LiuTet al. Functional identification of a novel 14-13-3 epsilon splicing variant suggests dimerization is not necessary for 14-13-3 epsilon to inhibit UV-induced apoptosis. Biochem. Biophys. Res. Commun.396, 401–406 (2010).
   PubMed Web of Science ®Google Scholar
• Wilker E , YaffeMB. 14-13-3 proteins – a focus on cancer and human disease. J. Mol. Cell Cardiol.37, 633–642 (2004).
   PubMed Web of Science ®Google Scholar
• Aitken A , BaxterH, DuboisTet al. Specificity of 14-13-3 isoform dimer interactions and phosphorylation. Biochem. Soc. Trans.30, 351–360 (2002).
   PubMed Web of Science ®Google Scholar
• Fu H , SubramanianRR, MastersSC. 14-13-3 proteins: structure, function, and regulation. Annu. Rev. Pharmacol. Toxicol.40, 617–647 (2000).
   PubMed Web of Science ®Google Scholar
• Yang X , LeeWH, SobottFet al. Structural basis for protein–protein interactions in the 14-13-3 protein family. Proc. Natl Acad. Sci. USA103, 17237–17242 (2006).
   PubMed Web of Science ®Google Scholar
• Lee CH , OuWB, Marino-EnriquezAet al. 14-13-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc. Natl Acad. Sci. USA109, 929–934 (2012).
   PubMed Web of Science ®Google Scholar
• Kruse AJ , CroceS, KruitwagenRFet al. Aggressive behavior and poor prognosis of endometrial stromal sarcomas with YWHAE–FAM22 rearrangement indicate the clinical importance to recognize this subset. Int. J. Gynecol. Cancer24, 1616–1622 (2014).
   PubMed Web of Science ®Google Scholar
• O’Meara E , StackD, LeeCHet al. Characterization of the chromosomal translocation t(10;17)(q22;p13) in clear cell sarcoma of kidney. J. Pathol.227, 72–80 (2012).
   PubMed Web of Science ®Google Scholar
• Chmielecki J , PeiferM, JiaPet al. Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Res.38, 6985–6996 (2010).
   PubMed Web of Science ®Google Scholar
• Mauro MJ , O’DwyerME, DrukerBJ. ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy. Cancer Chemother. Pharmacol.48(Suppl. 1), S77–S78 (2001).
   PubMedGoogle Scholar
• Kwak EL , BangYJ, CamidgeDRet al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med.363, 1693–1703 (2010).
   PubMed Web of Science ®Google Scholar
• Mazieres J , ZalcmanG, CrinoLet al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J. Clin. Oncol.33, 992–999 (2015).
   PubMed Web of Science ®Google Scholar
• Awad MM , KatayamaR, McTigueMet al. Acquired resistance to crizotinib from a mutation in CD74–ROS1. N. Engl. J. Med.368, 2395–2401 (2013).
   PubMed Web of Science ®Google Scholar
• Song A , KimTM, KimDWet al. Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer. Clin. Cancer Res.21, 2379–2387 (2015).
   PubMed Web of Science ®Google Scholar
• Davies KD , MahaleS, AstlingDPet al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS ONE8, e82236 (2013).
   PubMed Web of Science ®Google Scholar
• Cargnelutti M , CorsoS, PergolizziMet al. Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget6, 5182–5194 (2015).
   PubMed Web of Science ®Google Scholar
• Katayama R , KobayashiY, FribouletLet al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin. Cancer Res.21, 166–174 (2015).
   PubMed Web of Science ®Google Scholar
• Davare MA , SaborowskiA, EideCAet al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc. Natl Acad. Sci. USA110, 19519–19524 (2013).
   PubMed Web of Science ®Google Scholar
• Awad MM , ShawAT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin. Adv. Hematol. Oncol.12, 429–439 (2014).
   PubMedGoogle Scholar
• Narayanan R , YepuruM, CossCCet al. Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation. PLoS ONE8, e83380 (2013).
   PubMed Web of Science ®Google Scholar